Somatosensory Processing in Depression

April 13, 2015 updated by: Oliver Pogarell, Ludwig-Maximilians - University of Munich

Influence of Escitalopram on Somatosensory Processing in Patients With Major Depression

Aim of this study is to investigate neuronal differences (EEG/evoked potentials; functional MRI) between patients with major depression and healthy controls concerning brain activity after acute pain as well as changes of pain related brain activity during treatment with escitalopram.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
    • Bavaria
      • Munich, Bavaria, Germany, D - 80336
        • Department of Psychiatry and Clin. Radiology, Ludwig-Maximilian-University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Psychiatric in or outpatients with acute depressive episode
  • Indication for pharmacological treatment

Exclusion Criteria:

  • Acute suicidal tendency
  • Neurological or severe somatic disorders
  • Women during pregnancy or lactation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Treatment as usual
simultaneous EEG/fMRI
Procedure: simultaneous EEG/fMRI
fMRI/EEG recordings
Device: fMRI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
changes in evoked potentials/functional MRI from baseline to week 4
Time Frame: two assessments, at baseline and week 4
two assessments, at baseline and week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ludwig-Maximilians - University of Munich

Collaborators

H. Lundbeck A/S

Investigators

  • Principal Investigator: Ulrich Hegerl, MD, Department of Psychiatry, Ludwig-Maximilians-University
  • Principal Investigator: Oliver Pogarell, MD, Department of Psychiatry, Ludwig-Maximilians-University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2006

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

October 10, 2006

First Submitted That Met QC Criteria

October 10, 2006

First Posted (Estimate)

October 12, 2006

Study Record Updates

Last Update Posted (Estimate)

April 14, 2015

Last Update Submitted That Met QC Criteria

April 13, 2015

Last Verified

April 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ESC_03082005
  • 2005-003752-35

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on simultaneous EEG/fMRI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe